The changing landscape in the treatment of metastatic castration-resistant prostate cancer
The past few years have brought increasing advances in the therapeutic management of metastatic castration-resistant prostate cancer with the approval of several agents, including vaccine therapy with sipuleucel-T, second-line chemotherapy with cabazitaxel, the bone-targeted pharmaceutical denosumab...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | |
| التنسيق: | article |
| منشور في: |
2012
|
| الوصول للمادة أونلاين: | http://hdl.handle.net/10725/6239 http://dx.doi.org/ 10.1177/ 1758834012458137 http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php http://journals.sagepub.com/doi/abs/10.1177/1758834012458137 |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|